Inhibition of Delayed Cerebral Ischemia by Magnesium Is Insufficient for Subarachnoid Hemorrhage Patients: A Network Meta-Analysis
Objective. After subarachnoid hemorrhage, magnesium could reduce the incidence of delayed cerebral ischemia; however, it is still controversial. This study updated the results of recently published magnesium-related studies and conducted an exploratory analysis of the impact of application strategie...
Gespeichert in:
| Veröffentlicht in: | Evidence-based complementary and alternative medicine 2022-08, Vol.2022, p.1-15 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 15 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | Evidence-based complementary and alternative medicine |
| container_volume | 2022 |
| creator | Ba, Xiao-Hong Wang, Xiao-Di Dai, Yong-Yi |
| description | Objective. After subarachnoid hemorrhage, magnesium could reduce the incidence of delayed cerebral ischemia; however, it is still controversial. This study updated the results of recently published magnesium-related studies and conducted an exploratory analysis of the impact of application strategies and intervention factors on the results. Methods. Public databases were searched from the date of their inception to May 10, 2021. Randomized controlled trials on magnesium agent-related regimens for subarachnoid hemorrhage patients were included. Results. In total, 28 articles were included in the meta-analysis. For delayed cerebral ischemia, magnesium-related interventions significantly reduced the risk of delayed cerebral ischemia compared with nonmagnesium interventions (odds ratios: 0.40; 95% confidence interval: 0.28–0.56; p |
| doi_str_mv | 10.1155/2022/9357726 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9440634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2710972068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-9feb8c602e0c6c29093590a0aeb1be75e77924c63c46dce68a1edaaf633c5bbf3</originalsourceid><addsrcrecordid>eNp90U-L1DAYBvAiiruu3vwAAS-C1k3SNmk8CMP4Zwd2VVDBW3iTvp1mbZM1aV3m6ic3wwwLevCUkPx4yZOnKJ4y-oqxpjnnlPNzVTVScnGvOGWyZmXN2_b-3V5-PykepXRNKVdSyofFSSWoaLhkp8XvjR-ccbMLnoSevMURdtiRNUY0EUaySXbAyQExO3IFW4_JLVM-JRuflr531qGfSR8i-bIYiGAHH1xHLnAKMQ6wRfIZ5r1Jr8mKfMT5NsQf5ApnKFcexl1y6XHxoIcx4ZPjelZ8e__u6_qivPz0YbNeXZa2apq5VD2a1grKkVphuaI5s6JAAQ0zKBuUUvHaisrWorMoWmDYAfSiqmxjTF-dFW8Oc28WM2Emfs4J9U10E8SdDuD03zfeDXobfmlV11RUdR7w_Dgghp8LpllPLlkcR_AYlqTzh1IlORVtps_-oddhiTnwXlHVqLqVLKuXB2VjSClif_cYRvW-XL0vVx_LzfzFgQ_Od3Dr_q__AFiwpNA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2709594871</pqid></control><display><type>article</type><title>Inhibition of Delayed Cerebral Ischemia by Magnesium Is Insufficient for Subarachnoid Hemorrhage Patients: A Network Meta-Analysis</title><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Ba, Xiao-Hong ; Wang, Xiao-Di ; Dai, Yong-Yi</creator><contributor>Zhang, Xiangjian ; Xiangjian Zhang</contributor><creatorcontrib>Ba, Xiao-Hong ; Wang, Xiao-Di ; Dai, Yong-Yi ; Zhang, Xiangjian ; Xiangjian Zhang</creatorcontrib><description>Objective. After subarachnoid hemorrhage, magnesium could reduce the incidence of delayed cerebral ischemia; however, it is still controversial. This study updated the results of recently published magnesium-related studies and conducted an exploratory analysis of the impact of application strategies and intervention factors on the results. Methods. Public databases were searched from the date of their inception to May 10, 2021. Randomized controlled trials on magnesium agent-related regimens for subarachnoid hemorrhage patients were included. Results. In total, 28 articles were included in the meta-analysis. For delayed cerebral ischemia, magnesium-related interventions significantly reduced the risk of delayed cerebral ischemia compared with nonmagnesium interventions (odds ratios: 0.40; 95% confidence interval: 0.28–0.56; p<0.01). For cerebral vasospasm, a random effects model showed that magnesium significantly reduced the risk of cerebral vasospasm (odds ratios: 0.46; 95% confidence interval: 0.33–0.63; p<0.01). In the subgroup analysis, intracranial magnesium (odds ratios: 6.67; 95% confidence interval: 1.14–38.83; p=0.03) and magnesium plus hydrogen (odds ratios: 10; 95% confidence interval: 1.59–62.73; p=0.01) produced significant results in improving the good recovery rate compared to the control. In the network meta-analysis, magnesium plus nimodipine and simvastatin even showed an effective trend in death/persistent vegetative status improvement. Conclusion. This study supports the beneficial effect of magnesium in reducing the risk of delayed cerebral ischemia. Based on a single randomized controlled trial, immediate intracranial magnesium therapy with intravenous hydrogen after subarachnoid hemorrhage can increase the good recovery rate. Therefore, more high-quality studies are needed to confirm this finding.</description><identifier>ISSN: 1741-427X</identifier><identifier>EISSN: 1741-4288</identifier><identifier>DOI: 10.1155/2022/9357726</identifier><identifier>PMID: 36065271</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Bias ; Clinical trials ; Drug dosages ; Eclampsia ; Hemorrhage ; Intervention ; Intravenous administration ; Ischemia ; Magnesium ; Meta-analysis ; Mortality ; Neurosurgery ; Nimodipine ; Review ; Simvastatin ; Stroke ; Subarachnoid hemorrhage ; Vasoconstriction</subject><ispartof>Evidence-based complementary and alternative medicine, 2022-08, Vol.2022, p.1-15</ispartof><rights>Copyright © 2022 Xiao-Hong Ba et al.</rights><rights>Copyright © 2022 Xiao-Hong Ba et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Xiao-Hong Ba et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-9feb8c602e0c6c29093590a0aeb1be75e77924c63c46dce68a1edaaf633c5bbf3</citedby><cites>FETCH-LOGICAL-c355t-9feb8c602e0c6c29093590a0aeb1be75e77924c63c46dce68a1edaaf633c5bbf3</cites><orcidid>0000-0002-9235-8653</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440634/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440634/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids></links><search><contributor>Zhang, Xiangjian</contributor><contributor>Xiangjian Zhang</contributor><creatorcontrib>Ba, Xiao-Hong</creatorcontrib><creatorcontrib>Wang, Xiao-Di</creatorcontrib><creatorcontrib>Dai, Yong-Yi</creatorcontrib><title>Inhibition of Delayed Cerebral Ischemia by Magnesium Is Insufficient for Subarachnoid Hemorrhage Patients: A Network Meta-Analysis</title><title>Evidence-based complementary and alternative medicine</title><description>Objective. After subarachnoid hemorrhage, magnesium could reduce the incidence of delayed cerebral ischemia; however, it is still controversial. This study updated the results of recently published magnesium-related studies and conducted an exploratory analysis of the impact of application strategies and intervention factors on the results. Methods. Public databases were searched from the date of their inception to May 10, 2021. Randomized controlled trials on magnesium agent-related regimens for subarachnoid hemorrhage patients were included. Results. In total, 28 articles were included in the meta-analysis. For delayed cerebral ischemia, magnesium-related interventions significantly reduced the risk of delayed cerebral ischemia compared with nonmagnesium interventions (odds ratios: 0.40; 95% confidence interval: 0.28–0.56; p<0.01). For cerebral vasospasm, a random effects model showed that magnesium significantly reduced the risk of cerebral vasospasm (odds ratios: 0.46; 95% confidence interval: 0.33–0.63; p<0.01). In the subgroup analysis, intracranial magnesium (odds ratios: 6.67; 95% confidence interval: 1.14–38.83; p=0.03) and magnesium plus hydrogen (odds ratios: 10; 95% confidence interval: 1.59–62.73; p=0.01) produced significant results in improving the good recovery rate compared to the control. In the network meta-analysis, magnesium plus nimodipine and simvastatin even showed an effective trend in death/persistent vegetative status improvement. Conclusion. This study supports the beneficial effect of magnesium in reducing the risk of delayed cerebral ischemia. Based on a single randomized controlled trial, immediate intracranial magnesium therapy with intravenous hydrogen after subarachnoid hemorrhage can increase the good recovery rate. Therefore, more high-quality studies are needed to confirm this finding.</description><subject>Bias</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>Eclampsia</subject><subject>Hemorrhage</subject><subject>Intervention</subject><subject>Intravenous administration</subject><subject>Ischemia</subject><subject>Magnesium</subject><subject>Meta-analysis</subject><subject>Mortality</subject><subject>Neurosurgery</subject><subject>Nimodipine</subject><subject>Review</subject><subject>Simvastatin</subject><subject>Stroke</subject><subject>Subarachnoid hemorrhage</subject><subject>Vasoconstriction</subject><issn>1741-427X</issn><issn>1741-4288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp90U-L1DAYBvAiiruu3vwAAS-C1k3SNmk8CMP4Zwd2VVDBW3iTvp1mbZM1aV3m6ic3wwwLevCUkPx4yZOnKJ4y-oqxpjnnlPNzVTVScnGvOGWyZmXN2_b-3V5-PykepXRNKVdSyofFSSWoaLhkp8XvjR-ccbMLnoSevMURdtiRNUY0EUaySXbAyQExO3IFW4_JLVM-JRuflr531qGfSR8i-bIYiGAHH1xHLnAKMQ6wRfIZ5r1Jr8mKfMT5NsQf5ApnKFcexl1y6XHxoIcx4ZPjelZ8e__u6_qivPz0YbNeXZa2apq5VD2a1grKkVphuaI5s6JAAQ0zKBuUUvHaisrWorMoWmDYAfSiqmxjTF-dFW8Oc28WM2Emfs4J9U10E8SdDuD03zfeDXobfmlV11RUdR7w_Dgghp8LpllPLlkcR_AYlqTzh1IlORVtps_-oddhiTnwXlHVqLqVLKuXB2VjSClif_cYRvW-XL0vVx_LzfzFgQ_Od3Dr_q__AFiwpNA</recordid><startdate>20220826</startdate><enddate>20220826</enddate><creator>Ba, Xiao-Hong</creator><creator>Wang, Xiao-Di</creator><creator>Dai, Yong-Yi</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9235-8653</orcidid></search><sort><creationdate>20220826</creationdate><title>Inhibition of Delayed Cerebral Ischemia by Magnesium Is Insufficient for Subarachnoid Hemorrhage Patients: A Network Meta-Analysis</title><author>Ba, Xiao-Hong ; Wang, Xiao-Di ; Dai, Yong-Yi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-9feb8c602e0c6c29093590a0aeb1be75e77924c63c46dce68a1edaaf633c5bbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bias</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>Eclampsia</topic><topic>Hemorrhage</topic><topic>Intervention</topic><topic>Intravenous administration</topic><topic>Ischemia</topic><topic>Magnesium</topic><topic>Meta-analysis</topic><topic>Mortality</topic><topic>Neurosurgery</topic><topic>Nimodipine</topic><topic>Review</topic><topic>Simvastatin</topic><topic>Stroke</topic><topic>Subarachnoid hemorrhage</topic><topic>Vasoconstriction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ba, Xiao-Hong</creatorcontrib><creatorcontrib>Wang, Xiao-Di</creatorcontrib><creatorcontrib>Dai, Yong-Yi</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Evidence-based complementary and alternative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ba, Xiao-Hong</au><au>Wang, Xiao-Di</au><au>Dai, Yong-Yi</au><au>Zhang, Xiangjian</au><au>Xiangjian Zhang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of Delayed Cerebral Ischemia by Magnesium Is Insufficient for Subarachnoid Hemorrhage Patients: A Network Meta-Analysis</atitle><jtitle>Evidence-based complementary and alternative medicine</jtitle><date>2022-08-26</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>15</epage><pages>1-15</pages><issn>1741-427X</issn><eissn>1741-4288</eissn><abstract>Objective. After subarachnoid hemorrhage, magnesium could reduce the incidence of delayed cerebral ischemia; however, it is still controversial. This study updated the results of recently published magnesium-related studies and conducted an exploratory analysis of the impact of application strategies and intervention factors on the results. Methods. Public databases were searched from the date of their inception to May 10, 2021. Randomized controlled trials on magnesium agent-related regimens for subarachnoid hemorrhage patients were included. Results. In total, 28 articles were included in the meta-analysis. For delayed cerebral ischemia, magnesium-related interventions significantly reduced the risk of delayed cerebral ischemia compared with nonmagnesium interventions (odds ratios: 0.40; 95% confidence interval: 0.28–0.56; p<0.01). For cerebral vasospasm, a random effects model showed that magnesium significantly reduced the risk of cerebral vasospasm (odds ratios: 0.46; 95% confidence interval: 0.33–0.63; p<0.01). In the subgroup analysis, intracranial magnesium (odds ratios: 6.67; 95% confidence interval: 1.14–38.83; p=0.03) and magnesium plus hydrogen (odds ratios: 10; 95% confidence interval: 1.59–62.73; p=0.01) produced significant results in improving the good recovery rate compared to the control. In the network meta-analysis, magnesium plus nimodipine and simvastatin even showed an effective trend in death/persistent vegetative status improvement. Conclusion. This study supports the beneficial effect of magnesium in reducing the risk of delayed cerebral ischemia. Based on a single randomized controlled trial, immediate intracranial magnesium therapy with intravenous hydrogen after subarachnoid hemorrhage can increase the good recovery rate. Therefore, more high-quality studies are needed to confirm this finding.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>36065271</pmid><doi>10.1155/2022/9357726</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-9235-8653</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1741-427X |
| ispartof | Evidence-based complementary and alternative medicine, 2022-08, Vol.2022, p.1-15 |
| issn | 1741-427X 1741-4288 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9440634 |
| source | PubMed Central Open Access; Wiley Online Library Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Bias Clinical trials Drug dosages Eclampsia Hemorrhage Intervention Intravenous administration Ischemia Magnesium Meta-analysis Mortality Neurosurgery Nimodipine Review Simvastatin Stroke Subarachnoid hemorrhage Vasoconstriction |
| title | Inhibition of Delayed Cerebral Ischemia by Magnesium Is Insufficient for Subarachnoid Hemorrhage Patients: A Network Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T22%3A44%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20Delayed%20Cerebral%20Ischemia%20by%20Magnesium%20Is%20Insufficient%20for%20Subarachnoid%20Hemorrhage%20Patients:%20A%20Network%20Meta-Analysis&rft.jtitle=Evidence-based%20complementary%20and%20alternative%20medicine&rft.au=Ba,%20Xiao-Hong&rft.date=2022-08-26&rft.volume=2022&rft.spage=1&rft.epage=15&rft.pages=1-15&rft.issn=1741-427X&rft.eissn=1741-4288&rft_id=info:doi/10.1155/2022/9357726&rft_dat=%3Cproquest_pubme%3E2710972068%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2709594871&rft_id=info:pmid/36065271&rfr_iscdi=true |